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The  major, and according  to some authors  (1),  exclusive function  of class  I 
molecules of the  major  histocompatibility  complex  (MHC) l  is  to  guide  the  T 
lymphocytes. These molecules are necessary for the triggering, as well as for the 
effector function of cytotoxic T  lymphocytes (CTL) (2).  They are composed of 
a heavy glycoprotein chain with a molecular mass of 45 kilodaltons (kD), encoded 
by a  single  gene  within  or closely linked  to  the  MHC, and  the  noncovalently 
associated ~2  microglobulin  peptide  with  a  molecular  mass of 12  kD (3).  The 
heavy chain,  encoded by the H-2K, -D, or -L loci in mice is highly polymorphic 
and expressed on virtually all cells, including tumor cells. 
Tumor cells often show alterations in their expression of H-2 molecules when 
compared to cells in the corresponding normal tissue. The reported changes are 
either qualitative or quantitative.  The qualitative changes,  often referred to as 
alien H-2 antigens on tumor cells (4), represent a controversial issue which may 
be resolved by the use of monoclonal antibodies (mAb) and increased insights in 
the structure and organization of H-2 genes. The quantitative changes are easier 
to document and interesting also, since, in many cases, they are associated with 
functional  changes  of neoplastic  cells,  such as ability to grow progressively or 
metastasize in vivo (5-11). These changes have been discussed mainly in relation 
to immunosurveii[ance and MHC guidance of T  cells. It has been proposed (10) 
that reduced expression of one or several of the class I allelic products may allow 
tumor cells to escape detection by CTL. There may thus be a selection for such 
variants during  growth  in  vivo. There  is good evidence for this in the case of 
some immunogenic tumors (8, 9). However, loss of H-2 expression can also take 
place during growth in vitro, in the absence of any selective pressure from host 
factors (11-15).  Surprisingly,  H-2 expression is often regained if such lines are 
passaged in vivo (11, 15). Moreover, there are examples where tumor progression 
or metastasis are closely associated with increased expression of certain or all H- 
2  antigens  (5-7,  16).  One  explanation  of these  paradoxical  findings  is  that 
deletion or reduced expression of H-2 antigens reduces the ability of tumor cells 
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tO survive and spread in vivo through a mechanism that is independent of the T 
cell system. Such a  mechanism might have evolved to prevent the expansion of 
H-2-deficient variant clones,  which  would  otherwise represent a  danger  to  the 
organism  by  escaping  T  cell  recognition  after  virus  infection  or  malignant 
transformation 2 (17). To test this hypothesis, we selected lymphoma cells for loss 
of H-2 expression and compared these H-2-deficient variants with wild type cells 
for the ability to  grow as tumors in  mice.  After subcutaneous  inoculation  into 
syngeneic mice, the  H-2-deficient variants failed to  grow out as a  solid  tumor, 
whereas the H-2  + control line showed progressive growth at the site of inocula- 
tion. 2  In  this  report,  we  have  analyzed  the  mechanisms  behind  this  reduced 
ability to form tumors in vivo. The anti-H-2-resistant and original sublines were 
compared for in vitro growth parameters, as well as for short-term survival and 
outgrowth after injection into normal and immunodeficient mice. 
Materials and  Methods 
Animals.  Mice of the  following inbred  strains and F~  hybrids were bred and main- 
tained at the  Department of Tumor Biology, Karolinska Institute.  C57BL/6,  (A.BY × 
C57BL/6)Fb and (C57BL/6 x  C57L)FI, all H-2  wb. Atbymic nu/nu C57BL/6 mice were 
purchased from Bomholtgaarden, Denmark. All mice were 4-8 wk old at the start of the 
experiments. 
Tumors.  RBL-5 is a Rauscher virus-induced T  lymphoma, and EL-4 is a benzpyrene- 
induced  T  lymphoma. Both  are of C57BL/6  (H-2 b)  origin.  For selection  of anti-H-2- 
resistant  lymphoma variants,  tumor cells were mutagenized with  EMS  (ethyl  methane 
sulfonate) (Sigma Chemical Co., St. Louis, MO), 200/~g/ml for 72 h, washed twice, and 
cultured  1  wk  to  allow  for  cell  recovery.  The  cells  were  then  exposed  to  anti-H-2 
alloantisera  or  mAb,  plus  rabbit  complement (Cedarlane  Laboratories,  Ltd.,  Hornby, 
Ontario, Canada). The surviving cells were expanded and the procedure repeated. Several 
antibody-complement lytic selections were necessary to obtain stable H-2-1ow variants. All 
H-2-1ow variants used in this study have been selected at least five times, mAb against H- 
2K b (28-13-3S) and H-2D  b (28-14-8S) were obtained from the American Type Culture 
Collection, Rockville, MD (18).  All tumors were passaged as ascites lines in H-2-identical 
C57BL/6 or Fl-hybrid mice. For routine passages, the mice were irradiated (400 rad) 24 
h before tumor inoculation, to avoid immunoselection. 
Analysis of H-2 Expression.  Cell surface expression of H-2 was analyzed on a fluores- 
cence-activated cell sorter (FACS IV; Becton Dickinson Immunocytochemistry Systems, 
Mountain View, CA). For H-2 analysis, 5 X 105 cells were incubated with murine anti-H- 
2 mAb (culture supernatants) for 30 rain on ice, washed once, and incubated another 30 
min on ice with 200 ~1 fluorescein isothiocyanate (FITC)-labelled rabbit anti-mouse Ig 
(DAKO, Copenhagen, Demark) diluted 1:10 in balanced salt solution (BSS) supplemented 
with 20% fetal calf serum (FCS).  After three additional washings with BSS, the cells were 
analyzed on a FACS IV. The frequency and fluorescence of stained cells were determined 
using a  laser output  of 200  mW,  photo multiplier adjusted  to  600  V, and a  constant 
fluorescence gain for each series of samples. 
Treatment with Anti-asialo GMl Antiserum.  Natural killer (NK) cell deficiency in mice 
was induced by intravenous injections of rabbit anti-asialo GM1 antibody, Wako Chemi- 
cals, Dfisseldorf, Federal Republic of Germany (19).  30 #1 of the antiserum diluted in 0.2 
ml  BSS  was  injected  in  a  tail  vein  every  fourth  day,  starting  one  day  before  tumor 
challenge. A total of 3-5 injections were given. 
In Vivo Rejection Assay with |~5I-UdR-labelled Cells.  Tumor cells were labelled intraper- 
itoneally  with  125I-5-iodo-2-deoxyuridine  (Radiochemical  Centre,  Amersham  Corp., 
2 K/irre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. An alternative strategy for self/nonself 
discrimination? Host resistance directed selectively  against lymphoma variants with deleted or reduced 
H-2 expression. Manuscript submitted for publication. LJUNGGREN  AND  KARRE 
TABLE  I 
Nomenclature, Origin, and In Vitro Doubling Time of Lymphoma 
Cells Used in this Study 
Nomenclature  Mutageni-  Anti-H-2  In vitro 
used in this paper  zation  selection  doubling  Origin 
series  time (h) 
RBL-5  --  -  NT*  RBL-5 
RMA  A  -  14.4  RBL-5 
RMA H-2 sel  A  +  14.6  RBL-5 
RMB H-2 sel  B  +  15.8  RBL-5 
EL-4  --  -  NT  EL-4 
EMA  A  -  16.5  EL-4 
EMA H-2 sel  A  +  16.3  EL-4 
* NT, not tested. 
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Bucks, United Kingdom). 50 ~tCi were injected intraperitoneaily 3 d after intraperitoneal 
passage of 107 viable tumor cells into irradiated (400 rad) syngeneic mice. The cells were 
harvested and washed after 6 h. Syngeneic and F~ mice were injected in a lateral tail vein 
with  106 ~sI-UdR-labelled tumor cells in 0.2 ml BSS. The mice were killed at different 
time  intervals,  and  the  remaining radioactivity was measured  in  each  organ  in  a  LKB 
gamma counter, and expressed as percentage of total injected radioactivity. 
In Vivo Rejection Test.  Doses of 10s-10Otumor cells in a  0.1  ml volume of BSS were 
inoculated  subcutaneously  in  the  flank,  and  growth  was  followed by palpations  twice 
weekly. The tumors always appeared at the site of inoculation. In the initial experiments, 
tumors reaching more than  10 mm in mean diameter grew progressively. In subsequent 
experiments,  the mice were killed when the mean tumor diameter reached  15 mm and 
no signs of regression were seen. Mice without tumor growth were kept under observation 
for at least  8 wk after inoculation.  All tumor cells had been passaged as ascites lines in 
irradiated H-2  b/b homozygous C57BL/6 or F~ hybrid mice for several generations before 
inoculation. 
In Vitro Growth of Tumor Cells.  Tumor cells were seeded in 50-ml tissue culture flasks 
(3013; Falcon Labware, Oxnard, CA) in a concentration of 5 x  10 4 cells/ml (total volume, 
15 ml) in RPMI 1640 medium supplemented with penicillin-streptomycin and  10% FCS. 
Viable  cells  were  counted  in  trypan  blue  at  regular  intervals.  The  doubling time  was 
calculated  by exponential  regression  analysis.  The  experiments  were  repeated  several 
times with independently explanted cells. 
Cloning Efficiency In Vitro.  Tumor cells were seeded in 96-well tissue culture micro- 
plates with flat-bottom wells (3596; Costar, Cambridge, MA), starting with 256 cells/well 
in 0.1  ml RPMI 1640 medium supplemented with penicillin-streptomycin and  10% FCS. 
Dilutions  (1:2)  were  made,  ending  with  0.25  cells/replicate  well.  l0  d  after  seeding, 
cloning  efficiency was  scored  by counting  wells  with  viable  clones  visible  in  the  light 
microscope. 
Results 
Selection  and  Characterization  of Anti-H-2-resistant Lymphoma  Variants.  Anti- 
H-2-resistant variants have been selected from the C57BL/6-derived RBL-5 and 
EL-4 lymphomas. The wild type lymphoma cells were mutagenized, then exposed 
to anti-H-2  serum  plus  complement  in  several  selection  cycles to obtain  stable 
variants.  In this study, we used selected sublines from two independent mutagen- 
izations of the RBL-5 wild iype line,  and one from the EL-4 wild type line.  The 
normal  untreated  wild  type  lines,  as  well  as  mutagenized  but  nonselected  cell 
lines,  were  used  as  controls  (Table  I).  All  variants  used  in  this  study  showed a 1748  REDUCED  TUMORIGENICITY  OF  H-2-DEFICIENT  LYMPHOMAS 
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FIGURE  1.  FACS  analysis  of  H-2K  b  and  H-2D  b expression on  control  and  H-2-variant 
lymphoma cells after in vivo passage in syngeneic mice. 
profound reduction of H-2 cell surface antigens, as determined by serum absorp- 
tion assays,  FACS analysis, and  antibody plus complement-mediated  lysis with 
alloantisera  or mAb directed  against  H-2K  b,  H-2D  b,  or  ~2  microglobulin, z To 
avoid changes imposed by prolonged in vitro culture, we used cells that had been 
passaged in  vivo as ascites tumors  in  irradiated  mice in all experiments  in this 
study.  It was therefore  important  to first ascertain  that  the  variants  remained 
stable during such passages in vivo. The expression of H-2D  b and H-2K  b products, 
analyzed by separate reagents (Fig.  1), was still deficient after 30 in vivo passages. 
The in vivo- as well as the in vitro-passaged lines showed a marginal, insignificant 
increase in staining with specific antisera, compared to background staining with 
fluorescent conjugate alone  (not shown).  Quantitative  absorption  experiments 
performed recently (Ljunggren and K~irre, manuscript submitted for publication) 
indicate that this is due to a  low residual H-2 expression on all or a proportion 
of the variant cells. 
Growth and  Cloning Efficiency  In  Vitro.  There  was no significant  difference 
between the  control  lines  and  the  H-2-deficient  variants  in  growth  rate  after 
explantation  to tissue culture.  Growth curves from one of the observations with 
the RMA H-2 sel line and the unselected RMA control line are shown (Fig.  2). 
The lag period before exponential growth, as well as the maximal  cell concen- 
tration was similar for the two cell lines.  Similar results were obtained with the 
independently selected variants,  RMB H-2 sel and EMA H-2 sel;  no significant 
difference with regard  to in vitro doubling time,  lag periods, nor maximal  cell 
concentration  between the wild type control lines and the H-2-selected variants 
(Table I). 
In  addition,  no  significant  differences  in  cloning  efficiency  were  observed 
between the control lines and the H-2-selected variants of RBL-5 and EL-4.  In 
two independent  experiments,  with  EMA and  EMA H-2 sel, it was possible to 
observe  clones  of both  cell  lines  in  50%  of the  wells  10  d  after  seeding  4 
cells/well. A  similar pattern  was seen in  two independent  tests with  RMA and 
RMA H-2 sel, although  these lines required seeding of 8 cells/well to get 50% 
plating efficiency. LJUNGGREN AND KA,  RRE  1749 
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Tumor  Growth in Normal Mice.  Different doses of tumor cells (in  this study, 
103-106 cells) were injected subcutaneously in the flanks of mice in groups of 3- 
6 animals, usually littermates or otherwise age-matched within 2 wk. Rather than 
using large groups of mice in single experiments, we chose to use relatively small 
groups  of animals  in  several  independent  tests  throughout  the  study.  This 
minimized the risk that random fluctuations in the quality of control and variant 
cell suspensions would be responsible for differences in the ability to form tumors. 
After subcutaneous injections of the mutagenized but nonselected control line 
RMA (as well as the nonmutagenized  RBL-5 line) in doses of >103 cells, these 
lymphomas always grew out as solid tumors. EMA cells (and the nonmutagenized 
control,  EL-4) were somewhat less malignant,  growing in  30-70%  of the mice, 
depending on the injected dose. When tumors appeared, the growth was rapid, 
and a large solid tumor was palpable within 2-3 wk. The H-2-selected negative 
variants  of RBL-5 and  EL-4  (RMA  H-2  sel,  RMB H-2  sel, and  EMA H-2 sel) 
almost always failed to grow out as solid tumors under the same conditions (Fig. 
3). Doses of >--10  6 cells were needed to get more regular outgrowth of these H- 
2-deficient cells (not shown). This in vivo difference in tumor growth remained 
even when the RBL-5  H-2-deficient variant  and the control  line were injected 
subcutaneously in the opposite flanks of the same mouse (Table II, Exp.  1 and 
2). 
Tumor Growth in Irradiated Mice.  Irradiation (400 rads) before tumor grafting 
had a marginal effect on the rejection of 10 ~ cells. The same treatment abrogated 
the rejection  potential  against  104 cells (Table II,  Exp.  3 and  4), although  the 
outgrowth of 104 H-2-1ow variant cells in irradiated mice was delayed compared 
to  10 4  H-2 + cells (RMA median  latency period 8 d, range  7-9 d; RMA H-2 sel 1750  REDUCED  TUMORIGENICITY  OF  H-2-DEFICIENT  LYMPHOMAS 
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Tumor growth after subcutaneous injections of H-2  ÷ RBL-5 and EL-4 lymphoma 
lines, and H-2-1ow variants (RMA H-2 sel, RMB H-2 sel, and EMA H-2 sel) in three different 
doses, in syngeneic C57BL/6 or (C57BL/6 X A.BY)F] mice (one lymphoma type inoculated 
in each mouse).  The bars for H-2  ÷ control lines of RBL-5 and EL-4 each represent pooled 
data from tests with the untreated wild type lines, or mutagenized but nonselected lines. There 
were no differences in number of tumor takes or latency periods between the different types 
of control lines within each tumor. Only the B series of the RBL-5  H-2- variant (RMB H-2 
sel) has been tested with  l0  b cells. The figures indicate total numbers of mice with tumor 
growth per total number of mice injected with tumor cells. 
median  latency period  14  d,  range  10-35  d).  These  results  suggested  that  the 
reduced  tumorigenicity of H-2-variant  cells was  due  to a  host  mechanism  that 
was weakened,  but not completely abrogated  by 400-rad irradiation. 
Tumor Growth in T Cell-deficient Mice.  To determine  whether  the inability of 
H-2-1ow variant cells to grow out as solid tumors was T  cell-dependent,  syngeneic 
nude  mice (nu/nu) were inoculated with different doses of H-2-1ow variant and 
wild type control cells. The  tumor  cells were injected in separate animals, or in 
opposite flanks of the same mouse, as described above.  Reduced  tumorigenicity 
of the  H-2-deficient variant  (RMA  H-2  sel) was also observed in nude  mice.  In 
fact,  the  nude  mice appeared  even  more  resistant,  since they remained  tumor- 
free at  the  RMA  H-2  sei  inoculation  site even  after a  challenge  with  106  cells 
(Table II, Exp.  5  and 6). LJUNGGREN  AND  KARRE  1751 
TABLE  II 
Tumor Growth After Subcutaneous Injection of Wild Type and 
Variant Lymphoma Cells 
Number of  RMA H-2- 
Exp.  Mice  cells injected  RMA tu-  sel tumor 
into each  mot takes 
flank  takes 
(C57BL/6  × A.BY)FI  104  8/8  0/8 
(C57BL/6  × A.BY)F~  103  2/3  0/3 
2  (C57BL/6 × A.BY)F1  104  5/5  0/5 
3*  (C57BL/6  × A.BY)F~  104  5/5  -- 
(C57BL/6  × A.BY)F,  104  --  0/5 
(C57BL/6  × A.BY)Ft  104  5/5  -- 
irradiated 
(C57BL/6 × A.BY)F~  104  --  5/5 
irradiated 
(C57BL/6  × A.BY)F,  l0  s  5/5  -- 
(C57BL/6  X A.BY)Ft  103  --  0/5 
(C57BL/6  × A.BY)F~  10  ~  5/5  -- 
irradiated 
(C57BL/6  × A.BY)F~  103  --  2/5 
irradiated 
(C57BL/6 × A.BY)F~  103  5/5  0/5 
(C57BL/6 × A.BY)F~  103  5/5  2/5 
irradiated 
5*  C57BL/6 nu/nu  3 ×  105  4]4  -- 
C57BL]6 nu/nu  3 ×  10  ~  --  0]4 
C57BL/6 nu/nu  10  ~  4/4  0/4 
C57BL/6 nu/nu  105  2/4  0]4 
C57BL/6 nu/nu  104  1/4  0/4 
7  C57BL/6 anti-  104  4/4  4/4 
asialo GM1 
(C57BL/6  × A.BY)F~  104  5/5  0/5 
(C57BL/6  × A.BY)F~  104  3/3  3/3 
anti-asialo GM1 
RBL-5  wild type  and anti-H-2-resistant 
injected into opposite flanks of C57BL]6 
Successful tumor growth  was compared 
deficient, and NK-deficient mice. 
* Only one lymphoma type was inoculated 
variant lymphoma  cells were 
or (C57BL/6  × A.BY)FI mice. 
in normal, irradiated, T  cell- 
in each mouse. 
Tumor Growth in NK Cell-deficient Mice.  To determine whether the failure of 
the H-2-deficient cells to grow in vivo was dependent upon host NK cell activity, 
mice were  injected with anti-asialo GM1.  This antibody is directed against the 
glycolipid  asialo  GM1  expressed  on  the  cell  surface  of  NK  cells.  Microliter 
amounts of anti-asiaio GM1  depresses  NK cell activity in the spleen and other 
lymphoid organs (19). Mice were injected every fourth day with 25 ~1 of antibody, 1752  REDUCED  TUMORIGENICITY  OF  H-2-DEFIC1ENT  LYMPHOMAS 
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FmURE  4.  Survival of ]25I-UdR-labelled RMA  (H-2 +) and RMA  H-2  sel (H-2-)  lymphoma 
cells in syngeneic C57BL/6 mice 24 h after intravenous injection. The amount of radioactivity 
remaining in each organ indicated the distribution of surviving cells. Single observations are 
plotted (×) on a logarithmic scale, and the arithmetic mean is calculated (--). 
starting  1 d  before tumor challenge, and with a  total of 3-5 injections. In mice 
receiving this treatment,  the H-2-1ow variant grew progressively, like the H-2  + 
control line (Table II, Exp. 7 and 8). 
In Vivo Survival of lsotope-labeUed Lymphoma Cells.  Survival and organ distri- 
bution of the H-2  + RBL-5 control line (RMA) and the H-2-1ow variant (RMA H- 
2  sel)  in  vivo were studied  by monitoring remaining radioactivity in  different 
organs within  12-36 h  after intravenous injection of 125I-UdR-prelabelled cells. 
The  125I-UdR  is  rapidly released from dead cells, and excreted (20);  thus,  the 
amount  of radioactivity remaining  in  each  organ  indicates  the  distribution  of 
surviving  cells.  A  5-100-fold  difference was  observed  in  tumor  cell  survival 
between the RBL-5 control line and the variant in different experiments. These 
differences were  almost  abolished  when  the  mice  were  pretreated  with  anti- 
asialo  GMI  (Fig.  4).  This indicated that  NK cell activity was  necessary for the 
rapid elimination of the  RBL-5  H-2-1ow variant cells. The effect of anti-asialo 
GM~  injections was specific, and not due to injection of serum per se, since the LJUNGGREN  AND  KARRE 
TABLE  III 
Survival of 125I-UdR-labelled Tumor Cells in Syngeneic C57BL/6 
Mice Pretreated  with NRS 
Organ 
Percent of total injected radioactivity* 
RMA  RMA H-2 sel 
Lung  3.86 -+ 3.60  0.37 -+ 0.39 
Spleen  0.68 _+ 0.15  0.11 +  0.06 
Liver  4.04 +  2.75  0.64 +  0.64 
Kidney  0.29 4- 0.09  0.08 +- 0.06 
Hind leg  0.40 +  0.10  0.18 +  0.14 
GI tract  1.29 +  0.40  0.70 -+ 0.42 
Heart  0.07 +  0.07  0.02 +  0.01 
Brain  0.04 _  0.02  0.01  _  0.00 
Thymus  0.02 4" 0.01  0.02 -+ 0.01 
Thyroidea  0.13 -+ 0.00  0.10 +  0.04 
* Mean (+SD) radioactivity remaining 16 h after intravenous injection of 
RBL-5 wild type control line and anti-H-2-resistant  variant, using three 
mice per group. 
1753 
differences in survival between the lines were seen also in mice injected with 
normal rabbit serum (NRS) (Table III). The lower counts in liver, spleen, lung, 
and kidney in mice injected with RMA H-2 sel was not  just due to redistribution, 
since the amount of detectable radioactivity in other organs was negligible. 
Discussion 
Three lymphoma variants, selected independently for loss of H-2 expression, 
showed a significantly reduced ability to form tumors in vivo. In our attempts to 
analyze the mechanism behind this phenomenon, we failed to find any difference 
in  in  vitro  growth  properties  between  the  variant  lymphoma cells  and  their 
appropriate controls. The difference observed in vivo must therefore depend on 
interactions between the tumor cells and host factor(s). One testable interpreta- 
tion was that the variant and the wild type tumors were in fact equally sensitive 
to all possible host control mechanisms, and differed only in their ability to evoke 
a particular systemic host response. The H-2-deficient variant might thus have a 
unique ability to induce a tumor growth-inhibiting response, or lack the ability 
to  induce a  tumor growth-promoting response.  These  possibilities, however, 
were excluded in experiments where both tumors were injected simultaneously, 
in opposite  flanks, in  the same mouse.  Since the difference in  tumorigenicity 
remained under such conditions, it must be due to local tumor-host interactions, 
or to a difference in sensitivity to the same systemic host factor(s). 
Furthermore, the reduced tumorigenicity of the H-2- variant (RMA H-2 sel) 
did not depend on an intact T  cell system. It could be argued that the genetic T 
cell defect of nude mice is incomplete, since they have CTL precursors detectable 
under certain conditions in vitro (22).  However, it remains clear that nude mice 
have a strong relative T  cell defect in vivo (23).  Even if the variants were rejected 
by occasional T  cells in nude mice, we would not expect the nude mice to be 
even more resistant than the wild type mice and be able to reject a challenge of 
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RBL-5 challenge by preimmunizing  them with irradiated  cells from this tumor, 
we have so far not been able to protect mice from RBL-5, nor high doses of the 
variant cells by preimmunizing with the variants. 2 Taken together, these findings 
argue against the possibility that variant cells fail to grow because they evoke a 
strong adaptive T  cell response. They are thus different from the highly immu- 
nogenic  variants  of the  turn-negative  phenotype  derived after  mutagenization 
and cloning without selections, as described by several groups (24, 25). 
The strong in vivo resistance of nude mice is reminiscent  of earlier findings 
on their strong rejection potential against certain tumors, attributed to high NK 
cell activity (26).  Our general conclusion in this study is similar.  The effects of 
whole body irradiation  are consistent with  rejection  mediated by NK cells; an 
effector population with a limited life span, dependent on radiosensitive precur- 
sors,  but not necessarily on  proliferative  expansion  after  tumor grafting  (27). 
This  would explain  the  relatively radioresistant  rejection  of 103  cells,  while a 
dose of 104 cells would outnumber  the diminishing  effector cell population  in 
the absence of continuous influx from the precursor pool. We thus explain the 
reduced tumorigenicity of the H-2- variant cells by rapid natural killing in vivo. 
This was observable within  16-24 h after intravenous injection of radiolabeled 
cells into the animals.  These differences in rapid elimination  between the H-2- 
and  the  wild  type  cells were abrogated  by anti-asialo  GM1  serum,  known  to 
reduce  NK cell function  in  vivo (19).  Asialo GM~  is also expressed on a  small 
population of monocytes, and on some immature ceils of T  cell lineage (19, 28). 
However, taking into account experiments with radiation, nude mice, and natural 
killing  in  vivo,  the  results  strongly  support  a  model  wherein  cells  with  the 
functional  and  phenotypic  characteristics  of NK  cells are  responsible  for  the 
rejection.  It could also be argued that  the rapid elimination  would be relevant 
for  intravenous  disseminated  cells  only.  However,  anti-asialo  GM~  treatment 
also allowed the H-2- cells to form tumors after subcutaneous inoculation.  At 
this stage, we conclude that the reduced tumorigenicity is largely, if not entirely 
due to  NK-dependent  elimination,  regardless of the detailed events leading to 
the final triggering of tumor cell lysis. 
The  method  based on  in  vivo rejection  of radiolabelled  tumor  cells in  this 
paper was used previously (29-33) in studies of hybrid resistance,  and showed 
that  leukemic  cells failed  to survive  in  the  spleens  of mice  that  are  not  H-2- 
identical with the transplant (e.g. H-2  b cells in H-2  a'd or H-2  a'b hosts). In previous 
studies (34, 35) of the RBL-5 lymphoma, we found that it was highly malignant 
in syngeneic H-2  b'b hosts, whereas it was rejected in H-2  d'b hosts. Thus F1 hybrid 
resistance  (H-2  a'b rejecting  H-2  b) and  the  rejection  of syngeneic  H-2-deficient 
cells (H-2  b rejecting H-2-) seem to be mediated by the same mechanism, observ- 
able as natural  killing  within  24 h  after intravenous  injection,  and  sensitive to 
anti-asiaio GM~ (35). One interpretation,  reconciling the two different systems, 
is that the rejection is dependent upon failure of the grafted cells to present the 
histocompatibility antigens of the host.  NK-mediated rejection of H-2-deficient 
tumor variants  or MHC-disparate  bone marrow or lymphoid grafts (36) might 
then  be interpreted  to reflect a  recognition of incomplete self-H-2 expression z 
(17).  A  surveillance against  cells lacking  all  or a  part  of self-MHC would also 
explain why it is relatively difficult to select complete H-2- variants in vivo (37). LJUNGGREN AND K,~RRE  1755 
Preferential outgrowth of cells with reduced or deleted expression of certain H- 
2 alleles has however been observed for some virally induced, strongly antigenic 
tumors, for which T  cells presumably represent the major surveillance mecha- 
nism (8,  9,  38).  These experimental systems usually involve transplantation of 
large cell numbers (i.e.  105  cells or more), and  long latency periods,  both  of 
which may facilitate suppression of the NK-mediated defense or the acquisition 
of additional changes of the tumor cells, permitting their escape also from this 
system. One may compare the progressive growth of 106 H-2-deficient cells in 
this study, while 10-1,000-fold lower doses could be efficiently rejected in most 
mice. The lower doses might better correspond to the size of a variant population 
newly arising in vivo. Escape from a  surveillance against incomplete self could 
occur through selection for increased H-2 expression during tumor progression, 
thus explaining the paradoxical increase in the expression of class I MHC alleles 
associated with in vivo growth or metastasis in several experimental systems (5- 
7, 15). It is particularly the (re)expression of D-end alleles that has been associated 
with the metastatic phenotype (5-7).  This is interesting if it indeed refects an 
escape from a defense system that is also responsible for hybrid resistance and 
related to the NK cells. Both of the two latter phenomena are strongly influenced 
by genes mapping to the D  end of H-2 (31,  32,  39,  40).  In this context, it is 
interesting that low (or loss of) H-2 expression associated with increased malig- 
nancy more frequently involves the K-end locus (7, 8, 38). In some of the latter 
systems, recent studies with DNA-mediated gene transfer have provided direct 
evidence for the role of H-2K genes (38, 41, see also 42). Note however that the 
presence of H-2 would only be expected to delay or prevent growth of relatively 
antigenic tumors, probably a minority of spontaneous tumors (10). The rejection 
on the basis of H-2 deficiency suggested in this study would be independent of 
specific tumor antigens. 
We  have  previously  suggested  that  self-H-2  molecules may  constitute  (or 
contribute to the recognition of) an inhibitory signal in the NK-target interaction  2 
(17).  Lack of inhibitory influence would lead to preferential natural killing of 
such targets, thus giving the impression of recognition of absence of self. While 
our  results  indicate  that  the  H-2-deficient  cells  are  indeed  more  efficiently 
rejected by NK cells than their wild type counterparts in vivo, they do not prove 
the role of H-2 in control of NK sensitivity. At the host level, the NK-mediated 
elimination could be a  nonspecific consequence of earlier events, such as local 
recruitment and  activation  of effector cells  by  H-2-deficient tumor  cells,  or 
failure of these cells to  home correctly, leading to  increased exposure to  NK 
cells. We have recently observed that the H-2-deflcient variants are more suscep- 
tible to spontaneous spleen-mediated cytotoxicity than the wild type cells in vitro 
(RMA: mean 8% lysis, range 0-16%;  RMA H-2 sel: mean 28% lysis, range 15- 
45%). 2 This is in line with the possibility that loss of H-2 expression would affect 
the natural killing directly, although further studies focusing on the NK-target 
interaction and the role of other cells are required before any conclusions can 
be drawn. At the tumor cell level, a  direct relation between the H-2- and the 
NK-sensitive/tum-negative phenotype is attractive, but other possibilities  must 
also be considered. The MHC genes could influence the expression or recogni- 
tion of other cell surface molecules; our results may also merely reflect a common 1756  REDUCED  TUMORIGENICITY OF  H-2-DEFICIENT LYMPHOMAS 
regulation of MHC genes and genes influencing lymphoma cell interactions with 
host factors. The role of cell surface H-2 may be directly approached by molecular 
analysis of the regulatory or structural defects in H-2-variant cells, and by further 
manipulations  of their phenotype using cloned H-2 genes and their derivatives 
corresponding to truncated (43) or hybrid products (44). 
Summary 
Three  independent  variants  with  a  profound  reduction  of cell  Surface  H-2 
have  been  selected  from  the  C57BL/6  mouse-derived  RBL-5  and  EL-4  T 
lymphomas. After subcutaneous inoculation of low cell doses in syngeneic mice, 
the  H-2- variants  failed  to  grow  out,  whereas  the  H-2  + control  lines  showed 
progressive  growth.  No  difference  in  growth  rate  or  cloning  efficiency  was 
detectable  in  tissue  culture.  The  in  vivo difference  in  tumor  outgrowth  was 
analyzed  in  detail  for  one  of  the  H-2-1ow  lines.  The  outgrowth  difference 
remained  after  the  H-2-1ow  variant  and  the  control  line  had  been  injected 
subcutaneously in opposite flanks of the same mouse, and it was not dependent 
upon activity of mature T  cells, since the same result was seen in athymic nude 
mice.  The  difference was partially  sensitive  to irradiation  of the  hosts.  When 
mice were pretreated with anti-asialo GM1 antiserum,  known to depress natural 
killer (NK) cell activity, the difference in outgrowth was abolished, and both the 
control line and the H-2- variant showed progressive growth in vivo. Experiments 
comparing  the distribution  and  survival of isotope-prelabeled variant  and  wild 
type cells indicated that a rapid elimination  of the former took place Within  24 
h  after intravenous injection.  These differences in tumor elimination  were not 
seen in mice treated with anti-asialo GM1 antiserum. 
We conclude that the reduced tumorigenicity  of sublines with impaired  H-2 
expression  is  largely,  if not exclusively due  to  rapid  elimination  by NK  cells. 
These findings may reflect an inverse, indirect relation between factors control- 
ling  H-2  expression  and  NK  sensitivity.  Another  possible  explanation  is  that 
major  histocompatibility  complex  (MHC)-encoded  gene  products  are  directly 
involved in a regulatory signal in the NK cell system. According to this interpre- 
tation, immunological selectivity in the NK cell system would be achieved by the 
failure to recognize self-MHC, irrespective of the presence of foreign antigens, 
i.e. by detection of no-self rather than of nonself. This may also explain previous 
observations on H-2-1inked hybrid resistance against lymphoid grafts and changes 
in H-2 phenotypes associated with tumor progression. 
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